Oxidative Stress, Inflammation And Apolipoprotein B (Apo B): Risk Indicators of Cardiovascular Disease in Non Diabetic Obese Males

Dr. Sucheta Panda¹, Dr. Sharmistha Swain², Dr. Srikrushna Mahapatra¹a, Dr. Pramila Kumari Mishra¹, Dr. Nirupama Devi², Dr. Rasmita Padhy³, Dr. Roma Rattan³a

Abstract

Background and Objectives: Obesity is associated with dyslipidemia, altered apolipoprotein levels and chronic inflammation. The inflammatory markers (IL-1, TNF-alpha) in turn induce oxidative stress and hepatic synthesis of fibrinogen which is an active phase reactant and hence a marker of active inflammation in obesity. The increased levels of plasma fibrinogen lead to a hypercoagulable state inducing atherosclerosis and cardiovascular disease. Hence, this study was designed to evaluate lipid profile, apolipoprotein B (Apo B), fibrinogen and oxidative stress markers in non diabetic obese males.

Method: A case control study was done comprising of 45 non diabetic obese males and 45 healthy controls. Biochemical parameters measured in this study are fasting blood glucose, lipid profile (total cholesterol, triglycerider, HDL and LDL), apolipoprotein B, plasma fibrinogen, FOX2 and FRAP. Obesity expressed in terms of BMI and WHR.

Results: Obesity was significantly correlated with dyslipidemia, apolipoprotein B, inflammation and oxidative stress.

Conclusion: The present study identifies a pro artherogenic state in obesity as evidenced by a rise of lipid parameters, oxidative stress, Apo B and inflammatory marker.

Keywords: Apo B, fibrinogen, Oxidative stress, HTN.

I. INTRODUCTION

Obesity is the consequence of the interaction between social, behavioural, psychological, metabolic, cellular and molecular factors. (¹) Once a disease of developed nations, the rising incidence among the urban population of the developing and developed countries has been alarming. In 2008, 10% of men and 14% of women in the world were obese (BMI ≥30 kg/m²), compared with 5% for men and 8% for women in 1980. An estimated 205 million men and 297 million women over the age of 20 were obese – a total of more than half a billion adults worldwide. (²) Obesity predisposes individuals to an array of associated metabolic disorders such as artherosclerosis, coronary heart disease, dyslipidemia, gall bladder disease, hypertension, non-alcoholic fatty liver, type 2 diabetes mellitus and some types of cancer.

Increased oxidative stress (OS) in Obesity is due to NADPH-oxidase activation and deregulated production of adipocytokines like adiponectin, PAI-1, IL-6, and MAC-1; it has emerged as one of the principal causes of atherogenic modification in LDL lipoprotein. (³) It has been reported that obesity may induce systemic OS which in turn associated with an irregular production of adipokines, contributing to the development of the metabolic syndrome. The sensitivity of CRP and other biomarkers of oxidative damage are higher in obese and correlate directly with BMI and the percentage of body fat, LDL oxidation, and TG levels where as antioxidant defense markers are lower according to the amount of body fat and central obesity. Obesity is associated with a chronic inflammatory response, characterized by abnormal adipokine production, and the activation of some pro-inflammatory signaling pathways, there by resulting in the induction of several biological markers of inflammation. Obesity has also been associated with an increase in prothrombotic factors such as fibrinogen and decrease in fibrinolysis due to inhibitors like PAI-1. (⁴) The raised plasma FFA and inflammatory markers increase with obesity and stimulate fibrinogen synthesis in liver which contributes to increase in viscosity of blood, further aggravating the co-morbid state. Dyslipidemia are disorders of lipoprotein metabolism, including lipoprotein overproduction and deficiency. It is central to the adverse clinical consequences of adipocyte and adipose tissue dysfunction. (⁵) Obesity associated dyslipidemia may manifest as one or more of the following, elevated total cholesterol, low-density lipoprotein cholesterol (LDL), and triglyceride or as decreased high-density lipoprotein cholesterol (HDL) level with promotion of insulin resistance causing metabolic syndrome.

Apo B is a large hydrophobic, non exchangeable apolipoprotein playing an essential role in formation of triglycerol rich lipoproteins. (⁶) Metabolism of Apo B is hampered in obesity. (⁷) Elevated plasma level of
Apo B is strongly associated with raised risk of coronary artery disease and reflects increase in TG as well as the number of small density lipoprotein particles (VLDL, LDL).

**II. Materials And Methods**

The study included 45 non diabetic obese males and an equal number of age and sex matched controls who attended the outpatient department of medicine of M.K.C.G. Medical College and Hospital, Berhampur during the period of December 2013 to May 2015. Obese males were identified by either body mass index (BMI) > 30 Kg/m² OR waist to hip ratio (WHR) > 1.0 or both.

**Inclusion criteria**- Non diabetic obese male patients Exclusion criteria- All patients with chronic disorders like Diabetes, Hypertension, Thyroid disorders, Auto-immune disorder, smokers and persons taking lipid lowering drugs Biochemical analysis. Serum was used for analysis of Apolipoprotein B (Apo B), FOX 2, total cholesterol, triglyceride, HDL and LDL. Plasma was used for the analysis of FRAP, fibrinogen and glucose. All the tests were done within 8 hours of collection and separation of serum. Fasting blood glucose by glucose oxidase method, Lipid profile parameters such as total cholesterol, triglycerides, HDL,Cholesterol and LDL were measured by TOSHIBA-120FR procuring kit from AGAPPE diagnostics. The oxidative stress was evaluated by estimating the amount of oxidant load of lipid peroxides was determined by ferrous oxidation products in xylene orange assay in conjunction with triphenylphos

**Materials And Methods**

Antioxidant power of serum was measured by ferric reducing ability of serum (FRAP assay). Estimation of plasma fibrinogen by tyrosine method (lempert) Serum Apo B estimated by human apolipoprotien B (Apo-B) elisa kit.

Methods used to measure obesity in terms of body fat are: Body mass index (BMI) was calculated as weight (kg)/height (m²), BMI=Weight (Kg) / Height (m²)

**Standardized cut off points for overweight and obesity:** Normal weight is a BMI between 18.5 and 24.9; overweight is a BMI between 25.0 and 29.9; obesity is a BMI of 30.0 or higher. Waist-to-hip ratio (WHR) was measured as the ratio of the circumference of the waist to that of the hips. WHR is an indicator of abdominal obesity. The waist circumference measured at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest, hip circumference measured around the widest portion of the buttocks, with the tape parallel to the floor. According to WHO a WHR above 0.90 for males and above 0.85 for females considered as obese.

**III. Results**

Table 1 shows fasting blood sugar (FBS) of nondiabetic obese males and controls as 84.8 ± 7.2 mg/dl and 84.2 ± 5.1 mg/dl respectively with no significant correlation. The body mass index (BMI) of controls and nondiabetic obese males are (19.1 ± 3.6 kg/m²) and (31.6 ± 2.2 kg/m²) respectively which indicates a significant rise. There is a significant rise of waist to hip ratio (WHR) in nondiabetic obese males (1.01±0.01) as compared to controls (0.82±0.02). The comparison of mean of BMI and WHR of nondiabetic obese males and controls are shown in Graph 1(A) and Graph 1(B). A significant difference was observed in serum Total cholesterol (TC) level of nondiabetic obese males (218.4±29.1mg/dL) and controls (143.93 ± 20.7mg/dL). Triglyceride (TG) level of nondiabetic obese males (176.2 ± 75.5mg/dL) was found to be significantly higher than controls (108.8 ± 23.4mg/dL). A significant difference was seen between LDL levels of nondiabetic obese males (140.6 ± 29.4mg/dL) and controls (52.0 ± 22.7mg/dL). The HDL of nondiabetic obese males (43.2 ± 6.3mg/dL) found to be significantly lower than controls (60.0 ± 14.6mg/dL). The lipid profile of nondiabetic obese males and controls is shown in Graph 2.

Table 2 shows that Mean ± SD of FOX-2 as a measure of Total Oxidant Stress equivalent of H₂O₂ in μmol/L in nondiabetic obese males (3.8 ±0.3) was significantly higher than controls (2.9 ± 0.6) [shown in Graph 3(A )], while the Mean ± SD of FRAP as a measure of Total Plasma Antioxidant Capacity equivalent of ferrous sulphate in μmol/L was (561.8 ± 39.4) for nondiabetic obese males and (659.1 ±3.26) for controls respectively [ shown in Graph 3(B)].The table 3 and Graph 4 shows Mean ± SD of Fibrinogen as a marker of inflammation in nondiabetic obese males (256.9 ± 47.2mg/dl) was significantly higher than controls (178.3 ± 35.7mg/dl), while the Mean ± SD of Apo B100 was (151.66 ± 36.90 mg/dL) for nondiabetic obese males and (63.2 ± 17.9 mg/dL) for controls respectively. From Table 4 we found significant positive correlation of BMI with WHR(R²=0.835, p value <0.00), total cholesterol(TC)(R²=0.788, p value <0.00),TG(R²=0.482, p value <0.00), LDLCholesterol (R²=0.826, p value <0.00), FOX-2(R²=0.628, p value <0.00) as shown in Graph 14, Fibrinogen(R²=0.722, p value<0.00) as in Graph 15 and Apo B(R²=0.761, p value <0.00). There is significant negative correlation of BMI with HDL(R²=-0.613, p value <0.00) and FRAP(R²=-0.709, p value <0.00).

DOI: 10.9790/0853-1604033139 www.iosrjournals.org 32 | Page
The correlation of WHR is significantly positive with TC ($R^2=0.793$, p value $<0.00$), TG ($R^2=0.497$, p value $<0.00$), LDL ($R^2=0.850$, p value $<0.00$), FOX-2 ($R^2=0.628$, p value $<0.00$), Fibrinogen ($R^2=0.634$, p value $<0.00$) and Apo B ($R^2=0.822$, p value $<0.00$). There is significant negative correlation of WHR with HDL ($R^2=-0.600$, p value $<0.00$) and FRAP ($R^2=-0.793$, p value $<0.00$).

IV. Discussion
Early detection by simple and reliable anthropometric methods can help reverse or reduce the untoward effects of obesity. Anthropometric measurements are surrogate measures of body fat and are better predictors of dyslipidemia. In our study we observed a significant positive correlation between BMI and total cholesterol (TC) ($R^2=0.788$, p <0.01), triglyceride (TG) level ($R^2=0.482$, p <0.01), LDL ($R^2=0.826$, p <0.01) and significant negative correlation with HDL ($R^2=0.613$, p value <0.00) in nondiabetic obese males. Fatemeh et al (2014) in his study have found significant positive correlation of BMI with lipid parameters. Also Shashank et al (2014) and Fahim et al (2013) in their respective studies have found a significant positive correlation of dyslipidemia with obesity i.e. BMI. However the inability of BMI to correctly predict deranged lipid profile is in agreement with the study done by Shamai et al (2011) In the present study WHR (indicator of abdominal obesity) has a significant positive correlation with lipidemia in nondiabetic obese males i.e. TC ($R^2=0.793$, p value <0.01), TG ($R^2=0.497$, p value <0.01) and LDL ($R^2=0.850$, p value <0.01). This is in concurrence with studies by Oliveria et al (2010). The above findings suggest WHR to be more significant anthropometric measure to predict endogenous lipemia than BMI. Similar results are found in study done by Jabber et al (1997). Measurements of ApoB represent the total burden of the main lipoprotein particles involved in the atherosclerotic process. Increased synthesis of triglycerides in obese stimulate apolipoprotein B (Apo B) production that causes excess formation of VLDL-TG and VLDL-Apo B. In the present study we found a significantly raised Apo B level in nondiabetic obese males(151.66 ± 36.90) in comparison to controls(66.3 ± 17.9) with p value <0.05.Studies done by Taskinen et al (2011) and Panagiotakos et al, (2008) have similar findings.

The biomarkers of oxidative damage are higher in obese individuals and correlate directly with BMI, percentage of body fat, LDL oxidation, and TG levels. The increase in obesity associated oxidative stress(OS) is due to the presence of excessive adipose tissue itself, with the pre adipocytes and adipocytes as a source of proinflammatory cytokines, including TNF-α, IL-1 and IL-6, resulting a state of chronic inflammation. In the present study, FOX assay which measures the total oxidative load in the plasma is significantly raised with BMI. Total antioxidant capacity in our study measured in terms of FRAP assay is significantly decreased in nondiabetic obese males with increase in BMI as suggested by the study of Saida et al. (2014). Also Chrysohoou et al(2007), in their study reported that obese or overweight participants had lower TAC concentrations compared to normal individuals. A rise in FOX value and fall in FRAP value together constitutes the raise of oxidative stress in obesity.

Obesity with an increased amount of adipose tissue is associated with an increase in prothrombotic factors like fibrinogen and von Willebrand factor antigen (v WF:Ag). The high levels of fibrinogen in obese males can be explained by increase in its synthesis. The release of IL-6 by adipose tissue into the portal circulation influence the production of fibrinogen and other coagulation factors in the liver. Fibrinogen being a proinflammatory biomarker, a significant raise in its level suggests association of inflammation with obesity. In this study, significantly raised fibrinogen level in nondiabetic obese males (256.9 ± 47.2) compared to controls (178.3 ± 35.7) suggesting the presence of inflammation in obesity. Ezzat et al, (2006) in their study found that mean ± SD of plasma fibrinogen in obese males (282±38.6) significantly raised in comparison to controls (210±21.3) with a p value <0.05.

IV. Summary
The present study was conducted in the Department of Biochemistry, MKCG Medical College and Hospital, Berhampur with an objective to assess the state of dyslipidemia as measured by serum total cholesterol (TC), serum triglyceride (TG), serum LDL, serum HDL, and serum Apo B in nondiabetic obese males. These parameters were correlated with BMI and WHR as measures of obesity. We estimated FOX 2 as a measure of total oxidant load, plasma FRAP as a measure of total antioxidant capacity were correlated with each other and with body mass index (BMI) and waist to hip ratio (WHR). Fibrinogen as an inflammatory marker correlated with indicators of obesity and oxidative stress.

V. Conclusion
In the present study dyslipidemia is positively correlated with obesity which is statistically significant. Apo B is a marker for high level of circulating LDL which is atherogenic. In this study the serum Apo B was significantly increased compared to control group which refers to the fact that obese people are prone for atherosclerosis. There is a significant increase in oxidative stress in obesity. We found fibrinogen, as marker of...
chronic inflammation increasing significantly in obesity. Our study identifies a pro atherogenic state in obesity as evidenced by a rise of lipid parameters, oxidative stress marker i.e. rise in oxidant load and decrease in antioxidant level, Apo B and chronic inflammatory marker. Further larger study using all these parameters may guide in formulation of therapy in obesity to counter morbidity which could arise due to such metabolic derangements in obesity.

Bibliography


DOI: 10.9790/0853-1604033139 www.iiosjournals.org 34 | Page
Oxidative Stress, Inflammation And Apolipoprotein B (Apo B): Risk Indicators…


Table 1: Comparison of Biochemical parameters in Nondiabetic obese males and Controls

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Case Mean ± Sd</th>
<th>Control Mean ± Sd</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fbs(Mg/Dl)</td>
<td>84.8 ± 7.2</td>
<td>84.2 ± 5.1</td>
<td>0.076(Ns)</td>
</tr>
<tr>
<td>Bmi(Kg/M²)</td>
<td>31.6 ± 2.2</td>
<td>19.1 ± 3.6</td>
<td>0.003(S)</td>
</tr>
<tr>
<td>Whr(Cm/Cm)</td>
<td>1.01 ± 0.01</td>
<td>0.82 ± 0.02</td>
<td>0.00(S)</td>
</tr>
<tr>
<td>Chol(Mg/Dl)</td>
<td>218.4 ± 29.1</td>
<td>143.9 ± 20.7</td>
<td>0.03(S)</td>
</tr>
<tr>
<td>Tg(Mg/Dl)</td>
<td>176.2 ± 75.5</td>
<td>108.8 ± 23.4</td>
<td>0.00(S)</td>
</tr>
<tr>
<td>Ldl(Mg/Dl)</td>
<td>140.6 ± 29.4</td>
<td>52.0 ± 22.7</td>
<td>0.01(S)</td>
</tr>
<tr>
<td>Hdl(Mg/Dl)</td>
<td>43.2 ± 6.3</td>
<td>60.0 ± 14.6</td>
<td>0.00(S)</td>
</tr>
</tbody>
</table>

p value < 0.05 is considered significant.

Table 2: Comparison of FRAP and FOX in Nondiabetic obese males and Controls

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Case Mean ± Sd</th>
<th>Control Mean ± Sd</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frap(Mmol/L)</td>
<td>561.8 ± 39.4</td>
<td>659.1 ± 3.26</td>
<td>0.00</td>
</tr>
<tr>
<td>Fox (Mmol/L)</td>
<td>3.8 ± 0.3</td>
<td>2.9 ± 0.6</td>
<td>0.00</td>
</tr>
</tbody>
</table>

Table 3: Comparison of fibrinogen and Apo B in Nondiabetic obese males and Controls

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Case Mean ± Sd</th>
<th>Control Mean ± Sd</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibrinogen(Mg/Dl)</td>
<td>256.9 ± 47.2</td>
<td>178.3 ± 35.7</td>
<td>0.02</td>
</tr>
<tr>
<td>Apo B 100(Mg/Dl)</td>
<td>151.6 ± 36.90</td>
<td>66.3 ± 17.9</td>
<td>0.00</td>
</tr>
</tbody>
</table>

Table 4: Pearson Correlation of BMI and WHR with lipid parameters, FRAP, FOX, Fibrinogen and Apo B

![Graph1 (A): Means Of Bmi In Nondiabetic Obese Males And Controls](image)

DOI: 10.9790/0853-1604033139
Oxidative Stress, Inflammation And Apolipoprotein B (Apo B): Risk Indicators...

**WHR**

![Graph1 (B): Means Of WHR In Nondiabetic Obese Males And Controls](image)

### MEANS OF CHOLESTEROL, TRIGLYCERIDE, LDL AND HDL IN CASES AND CONTROLS

![Graph 2: Means Of Total Cholesterol, Triglycerides, Ldl And Hdl In Cases And Controls](image)

### FOX VALUES IN NON DIABETIC OBESE MALES AND CONTROLS

![Graph3 (A): Mean Values Of Frap In Nondiabetic Obese Males And Controls](image)
FRAP IN NON DIABETIC OBSESE MALES AND CONTROLS

Graph 3 (B): Mean Values Of Fox In Nondiabetic Obese Males And Controls

MEANS OF FIBRINOGEN AND APO B IN CASES AND CONTROLS

Graph 4: Means Of Fibrinogen And Apo B In Nondiabetic Obese Males And Controls

CORRELATION OF LIPID PROFILE WITH BMI IN NON DIABETIC OBSESE MALES AND CONTROLS

Graph 5: Correlation Of Lipid Profile With Bmi In Nondiabetic Obese Males And Controls
Graph 6: Correlation Of Lipid Profile With Whr In Nondiabetic Obese Males And Controls

Graph 7: Correlation Of Bmi With Frap And Fox2

Graph 8: Correlation Of Whr With Frap And Fox2
**Graph 9:** correlation of apo b with bmi and whr in non-diabetic obese males and controls

**Graph 10:** Correlation Of Fibrinogen With Bmi In Nondiabetic Obese Males And Controls